Skip to main content Skip to navigation
Department of Chemistry Jones Research Group
  1. Khani-Oskouee, S., Jones, J.P., and Woodard, R.W.  Stereochemical course of the biosynthesis of 1-aminocyclopropane-1-carboxylic acid.  I.  The role of the asymmetric sulfonium pole and the α-amino acid center.  Biochem. Biophys. Res. Commun, 1984. 121: 181-187.
  2. Jones, J.P., Korzekwa, K.R., Rettie, A.E., and Trager, W.F.  Isotopically sensitive branching and its effect on the observed intramolecular isotope effects in cytochrome P-450 catalyzed reactions:  A new method for the estimation of the intrinsic isotope effect.  J. Amer. Chem. Soc, 1986 108:  7074-7078.
  3. Jones, J.P., and Trager, W.F.  The separation of the intramolecular isotope effect for the cytochrome P-450 catalyzed hydroxylation of octane into its primary and secondary components.  J. Amer. Chem. Soc., 1987 109:  2171-2173.
  4. Trager, W.F., and Jones, J.P. Stereochemical considerations in drug metabolism.  In:  Progress in Drug Metabolism (Bridges J.W., Chasseaud C.F., and Gibson, G., eds.), Taylor and Francis, London, 1987, vol. 10, pp. 101-129. (Invited Review)
  5. Jones, J.P., Rettie, A.E., and Trager, W.F.  Intrinsic isotope effects suggest that the reaction coordinate symmetry for the cytochrome P-450 catalyzed hydroxylation of octane is isozyme independent.  J. Med. Chem., 1990 33:  1242-1246.
  6. Korzekwa, K.R., Jones, J.P., and Gillette, J.R. Theoretical studies on cytochrome P-450 mediated hydroxylation:  A predictive model for hydrogen atom abstractions.  J. Amer. Chem. Soc., 1990 112: 7042-7046.
  7. Wimmer, M.J., Smith, R.R., and Jones, J.P.  Analysis of diflubenzuron by gas chromatograph/mass spectrometry using deuterated diflubenzuron as internal standard.  J. Agr. Food Chem, 1991, 39: 280-286.
  8. Jones, J.P., and Urbauer, J.L..  Theoretical kinetic isotope effects for hydride transfer from formate to carbon dioxide:  A comparison of theory with experiment.  J. Comp. Chem. Soc., 1991, 12: 1134-1141.
  9. Jones, J.P., Weiss, P.M., and Cleland, W.W.  Secondary 18O isotope effects for the hexokinase catalyzed phosphoryl transfer from ATP.  Biochemistry, 1991 30: 3634-3639.
  10. Harris, J.W., Jones, J.P., Martin, J.L., Larosa, A.C., Olson, M.J., Pohl, L.R. and Anders, M.W.  Pentahaloethane-based chlorofluorocarbon substitutes and halothane: Correlation of in vivo hepatic protein-trifluoroacetylation and urinary trifluoroacetic acid production with calculated enthalpies of activation. Chem. Res. Toxicol, 1992, 5: 720-725.
  11. Jones, J.P., Trager, W.F., Carlson, T.J.  The binding and regioselectivity of reaction of (R)- and (S)-nicotine with cytochrome P-450cam: Parallel experimental and theoretical studies. J. Amer. Chem. Soc, 1993 115: 381-387.
  12. Korzekwa, K.R., and Jones, J.P.  Predicting the cytochrome P450 mediated metabolism of  xenobiotics. Pharmacogenetics, 1993  3: 1-18. (Invited Review)
  13. Dinnocenzo, J.P., Karki, S.B. and Jones, J.P.  Isotope effects for the cytochrome P-450 oxidation of substituted N,N-dimethylanilines. J. Amer. Chem. Soc, 1993. 115: 7111-7116.
  14. Yin, H., Jones, J.P. and Anders, M.W.  Slow-binding inhibition of carboxyesterase and other serine hydrolases by chlorodifluoroacetaldehyde. Chem. Res. Toxicol, 1993. 6: 630-634.
  15. Yin, H., Bennett, G., Jones, J.P.  Mechanistic studies of UDP-glucuronyltransferase. Chem. Biol. Inter., 1994, 90: 47-58.
  16. Goldstein, B.M., Li, H., Jones, J.P., Bell, J.E., Zeidler, J., Pankiewicz, K.W., Watanabe, K.A.  CNAD: A potent and specific inhibitor of alcohol dehydrogenase. J. Med. Chem. , 1994, 37: 392-399.
  17. Jones, J.P., Shou, M., Korzekwa,K.R.  Stereospecific activation of the procarcinogen benzo[a]pyrene: A probe for the active sites of the cytochrome P450 superfamily. Biochemistry, 1995,  34: 6956-6961.
  18. Dinnocenzo, J.P., Karki, S.B., Jones, J.P., Korzekwa, K.R.  The mechanism of oxidative amine dealkylation by cytochrome P450: application of isotope effect profiles. J. Amer. Chem. Soc., 1995, 117: 3657-3664.
  19. Yin, H., Jones, J.P., Anders, M.W.  Metabolism of 1,1,1,trifluoro-2-chloroethane, 1,2-dichloro-1,1-difluoroethane, and 1-fluoro-1,1,2-trichloroethane. Chem. Res. Toxicol, 1995, 8: 262-268.
  20. Zatorski, A., Goldstein, B.M., Colby, T.D., Jones, J.P., Pankiewicz, K.W.  Potent Inhibitors of Human Inosine Monophosphate Dehydrogenase Type II. Fluorine-Substituted Analogues of Thiazole-4-carboxamide Adenine Dinucleotide.  J. Med. Chem, 1995, 38: 1098-1105.
  21. Carlson, T.J., Jones, J.P., Peterson, L., Castagnoli, N., Iyer, K., Trager, W.F.  Stereoselectivity and isotope effects associated with cytochrome P450 catalyzed oxidation of (S)-nicotine: The possibility of initial hydrogen atom abstraction in the formation of the 1’,5’-nicotinium Ion. Drug Metab. and Disp., 1995, 23: 749-756.
  22. Yin, H., Anders, M.W., Higgins, L.A., J., Korzekwa, K.R., Kharasch, E., Thummel, K., Jones, J.P.  Designing safer chemicals: a model for predicting the rates of halogenated hydrocarbon metabolism. Proc. Nat. Acad. Sci. (USA), 1995, 92: 11076-11080.
  23. Yin, H., Anders, M.W., Jones. J.P.  Metabolism of 1,2-dichloro-1-fluoroethane and 1-fluoro-1,2,2-trichloroethane: Electronic factors govern the regioselectivity of cytochrome P450-dependent oxidation. Chem. Res. Toxicol,1996,, 9: 50-57.
  24. Yin H. Crowder RJ. Jones JP. Anders MW. Reaction of trifluoroacetaldehyde with amino acids, nucleotides, lipid nucleophiles, and their analogs. Chem. Res. Toxicol. 9(1):140-6, 1996.
  25. Jones, J.P., He, M., Trager, W.F., Rettie, A.E. 3D-QSAR for Inhibitors of Cytochrome P450 2C9. Drug Metab. Disp., 1996, 24: 1-6.
  26. Jones, J.P., Shou, M., Korzekwa, K.R.  Predicting the regioselectivity and  stereoselectivity of cytochrome P450-mediated reactions. Invited chapter in “Biological Intermediates V: Basic Mechanistic Research in Toxicology and Human Risk Assessment.”  Editors: Robert Synder et al., 1996, pp. 355-361. Plenum Publishing, New York, N.Y.
  27. Anders, M.W., Yin, H., Jones, J. P.  Applications of Computational chemistry in the study of biologically reactive intermediates. Invited chapter in “Biological Intermediates V: Basic Mechanistic Research in Toxicology and Human Risk Assessment.”  Editors: Robert Synder et al., 1996, pp. 347-353. Plenum Publishing, New York, N.Y.
  28. Korzekwa, K. R., Grogan, J., DeVito, S. and Jones, J.P.  Electronic models for cytochrome P450 oxidations. Invited chapter in “Biological Intermediates V: Basic Mechanistic Research in Toxicology and Human Risk Assessment.”  Editors: Robert Synder et al. , 1996, pp. 361-369. Plenum Publishing, New York, N.Y.
  29. Jones, J.P.  Predicting rates of bioactivation by cytochrome P450 and its application to the design of safer chemicals. Invited chapter in “Designing Safer Chemicals.” Editors: S. Devito & R. Garrett. Invited Chapter, 1996,  pp. 116-137. ACS Books Washington D.C.
  30. Jones, J.P. and Korzekwa, K.R. Predicting binding affinities and rates of reaction for the P450 superfamily.  Invited Chapter, in “Methods in Enzymology” Editors E.F. Johnson & M. R. Waterman. Vol. 272b, pp. 326-335.
  31. Manchester, J. I., Dinnocenzo, J.P., Higgins, L. and Jones, J.P.  A new mechanistic probe for cytochrome P450.  J. Amer. Chem. Soc., 1997,  119: 5069-5070.
  32. Iyer, K.R., Jones, J.P., Darbyshire, J.F., Trager, W.F.  Intramolecular isotope effects for benzylic hydroxylation of isomeric xylenes and 4,4’-dimethylbiphenyl by cytochrome P450: Relationship between distance of methyl groups and masking of the intrinsic isotope effect.  Biochemistry, 1997,  36: 7136-7143.
  33. Higgins, L, Bennett, G. A., Shimoji, M. & Jones, J.P. Evaluation of Cytochrome P450 Mechanism and Kinetics Using Kinetic Deuterium Isotope Effects.  Biochemistry, 1998, 37, 7036-7046.
  34. Shimoji, M., Yin, H., Higgins, L. Jones, J.P. Design of a Novel P450: A Functional Bacterial/Human Cytochrome P450 Chimera. Biochemistry, 1998, 37, 8848-8852. *This paper was determined to be of outstanding significance by Current Opinions in Structural Biology, Vol 8, p. 540, 1998.
  35. Goto, Y., Watanabe, Y., Fukuzumi, S., Jones, J. P. Dinnocenzo, J. P. Mechanisms of N-Demethylations Catalyzed by High-Valent Species of Heme Enzymes: Novel Use of Isotope Effects and Direct Observation of Intermediates. J. Amer. Chem. Soc., 1998, 120: 10762-10763.
  36. Halpert, J.R., Domanski, T.L., Adali, O., Biagini, C.P., Cosme, J. , Dierks, E. A., Johnson, E. F., Jones, J. P., Ortiz De Montellano, P., Philpot, R. M., Sibbesen, O., Wyatt, W. K., Zheng, Z., Structure-Function of Cytochrome P450 and Flavin-Containing Monooxygenases., Drug Metab and Disp, 1998, 26, 1223-1231.
  37. Audergon, C., Iyer, K.R., Jones, J.P., Darbyshire, J.F, Trager, W.F.  Experimental and theoretical approaches to study the active site topography of CYP101 (P450cam).  J. Amer, Chem. Soc , 1999 121, 41-47.
  38. Haining, R.L., Jones, J.P., Henne, K., Fisher, M.B.,  Trager, W.F., Rettie, A.E. Phenylalanine 114 is a Critical, Substrate-Dependent Determinant of Specificity in Human Cytochrome P450 2C9. Biochemistry, 1999, 38, 3285-3292.
  39. Henry, E. C., Kende, A. S.,  Rucci, G., Totleben, M. J., Willey, J.J., Dertinger, S.D., Pollenz, R. S., Jones, J. P., Gasiewicz T.A. Flavone Antagonists Bind Competitively with 2,3,7,8-Tetrachlorodibenzo-p-Dioxin (TCDD) to the Aryl Hydrocarbon Receptor But Inhibit Nuclear Uptake and Transformation. Mol Pharmacol, , 1999, 55, 716-725.
  40. He, M., Korzekwa, K.R., Jones, J. P., Trager, W.F. Active Site Structural Forms of Warfarin and Phenprocoumon that are Metabolized by CYP2C9. Arch Biochem Biophysics, 372, 16-28, 1999.
  41. Burke WD, Malik HS, Jones JP, Eickbush TH, The domain structure and retrotransposition mechanism of R2 elements are conserved throughout arthropods. Mol Biol Evol, 1999, 16, 502-511.
  42. Goto Y, Matsui T, Ozaki SI, Watanabe Y, Fukuzumi S, Dinnocenzo JP, Jones JP. Reaction mechanisms of N-demethylation and sulfoxidation catalyzed by heme enzymes, J. Inorg.  Biochem, 1999, 74, 146-146.
  43. Koenigs, L.L., Jones, J.P., Friedberg, T., Pritchard, M. P., Shou, M., Rushmore, T.H., Trager, W. F. Mechanism-Based Inactivation of Cytochrome P450 3A4 by L-754,394.  Biochemistry, 2000;39:4276-87.
  44. Rao S, Aoyama R, Schrag M, Trager WF, Rettie A, Jones JP, A refined 3-dimensional QSAR of cytochrome P450 2C9: computational predictions of drug interactions. J Med Chem. 2000;43:2789-96.
  45. Higgins, L., Korzekwa, K.R., Shou, M., Jones, J.P. A Method for the Assessment of Reaction Energetics for Cytochrome P450 Mediated Reactions. Arch Biochem Biophys, 2001, 385, 220-230.
  46. Ekins, S., de Groot, M.J., Jones, J.P. Pharmacophores and three Dimensional Quantitative Structure Activity Relationship Methods for Modeling Cytochrome P450 Active Sites. Drug Metab and Disp, 2001, 29, 936-944.
  47. Rock D, Rock D, Jones JP.  Inexpensive purification of P450 reductase and other proteins using 2 ‘,5 ‘-adenosine diphosphate agarose affinity columns. Prot. Express. Pur. , 2001, 22: 82-83.
  48. Sathyanarayana, P.V., Siems, W.F., Jones, J.P., Poovaiah, B. W. Calcium-stimulated atuophosphorylation site of plant chimeric calcium/calmodulin dependent protein kinase.  J. Biol. Chem. 2001, 276, 32940 – 32947.
  49. French, K. J., Strickler, M. D., Rock, D. A., Rock, D. A., Bennett, G. A., Wahlstrom, J. L. Goldstein, B. M., Jones, J. P.  Benign Synthesis of 2-ethylhexanoic acid by Cytochrome P450cam: Enzymatic, Crystallographic, and Theoretical Studies.  Biochemistry, 2001; 40; 9532-9538.
  50. Christmas, P., Jones, J. P., Patten, C. J., Zheng, Y., Cheng, S., Weber, B. M., Carlesso, N., Scadden, D. T., Rettie, A.E., Soberman, R.J.  Alternate Splicing Determines the Function of CYP4F3 by Switching Substrate Specificity.  J. Biol. Chem. 2001; 276, 38166-72.
  51. Xu C, Rao YS, Xu B, Hoffmann E, Jones J.P., Sellers EM, Tyndale RF An In Vivo Pilot Study Characterizing the New CYP2A6*7, *8, and *10 alleles.  Biochem. Biophys. Res. Comm.
  52. Kevin J. French, Dan A. Rock, Denise A. Rock, John I. Manchester, Barry M. Goldstein, and Jeffrey P. Jones* “Rational Design of Cytochrome P450cam: Understanding the structural basis for the oxidase shunt and improving the benign synthesis of 2-Ethylhexanoic Acid” Arch. Biochem. Biophys. 2002, 398, 188-97.
  53. Jeffrey P. Jones*, Michael Mysinger, Kenneth Ray Korzekwa “Computational Models for Cytochrome P450: A Predictive Electronic Model for Aromatic Oxidation and Hydrogen Atom abstraction” Drug Metab. Disp.  2002, 1, 7-12. (Won best paper of the year award.)
  54. Dan A. Rock, Anthony E. Boitano, Jan L. Wahlstrom, Denise A. Rock, and Jeffrey P. Jones* “The Use of Kinetic Isotope Effects to Delineate the Role of Phenylalanine 87 in P450BM-3 “  Bioorganic Chemistry, 2002; 30,  107-118.
  55. Volz, T., Rock, D.A., Jones, J.P.“Direct Evidence for Two Different Active Oxygen Species in Cytochrome P450BM3 Mediated Sulfoxidation and N-Dealkylkation Reactions.” J Amer Chem Soc.2002, 124(33); 9724-9725.
  56. Strickler M, Goldstein BM, Maxfield K, Shireman L, Kim G, Matteson DS, Jones JP. “ Crystallographic studies on the complex behavior of nicotine binding to P450cam (CYP101).” Biochemistry. 2003 Oct 21;42(41):11943-50
  57. Locuson CW, Wahlstrom JL, Rock DA, Rock DA, Jones JP “A new class of CYP2C9 inhibitors: Probing 2C9 specificity with high-affinity benzbromarone derivatives.” Drug Metab. and Disp.  31 (7): 967-971 JUL 2003.
  58. Rock DA, Perkins BNS, Wahlstrom J, Jones JP.  “A method for determining two substrates binding in the same active site of cytochrome P450(BM3): an explanation of high energy omega product formation.” Arch. Biochem. Biophys. 416 (1): 9-16 Aug 1 2003.
  59. Tornero-Velez R, Ross MK, Granville C, Laskey J, Jones JP, DeMarini DM,Evans MV “Metabolism and mutagenicity of source water contaminants 1,3-dichloropropane and 2,2-dichloropropane” Drug Metab. and Disp. 32 (1): 123-131 JAN 1 2004.
  60. Dowers TS, Rock DA, Rock DA, Perkins BNS, Jones JP.  “An analysis of the regioselectivity of aromatic hydroxylation and N-oxygenation by cytochrome P450 enzymes.” Drug Metab. and Disp. 32 (3): 328-332, 2004.
  61. Dickmann, L. J., Locuson, C. W., Jones, J. P. and Rettie. A.E., “Differential Roles of Arg97, Asp293, and Arg108 in Enzyme Stability and Substrate Specificity of CYP2C9.” Mol Pharmaco,l 65: 842-850, 2004.
  62. Locuson,C.W. II, Rock, D.A., and Jones, J.P., “Quantitative Binding Models for CYP2C9 Based on Benzbromarone Analogues, Biochemistry, (2004); 43(22); 6948-6958.
  63. Dowers, T. S., D. A. Rock, D. A. Rock and J. P. Jones (2004). “Kinetic isotope effects implicate the iron-oxene as the sole oxidant in P450-catalyzed N-dealkylation.” J Amer Chem Soc, 126(29): 8868-8869.
  64. Jones, J. P.. “Metabolic menages a trois: what does it mean for drug design?” Invited commentary, Drug Discovery Today 9(14): 592-592 (2004).
  65. Locuson, C. W., H. Suzuki, A. E. Rettie and J. P. Jones (2004). “Charge and substituent effects on affinity and metabolism of benzbromarone-based CYP2C19 inhibitors.” J Med Chem, 47(27): 6768-6776.
  66. Suzuki, H., M. B. Kneller, D. A. Rock, J. P. Jones, W. F. Trager and A. E. Rettie (2004). “Active-site characteristics of CYP2C19 and CYP2C9 probed with hydantoin and barbiturate inhibitors.” Arch Biochem and Biophysics 429(1): 1-15.
  67. Rettie, A., Jones, J.P. (2005) “Clinical and toxicological relevance of CYP2C9: Drug- drug interactions and pharmacogenetics” Annual Review of Pharmacology and Toxicology 45 477-494.
  68. Hudelson MG, Jones JP. (2006) “Line-walking method for predicting the inhibition of p450 drug metabolism.” J Med Chem. 2006 Jul 13;49(14):4367-73.
  69. Dowers TS, Jones JP (2006) “Kinetic isotope effects implicate a single oxidant for cytochrome P450-mediated O-dealkylation, N-oxygenation, and aromatic hydroxylation of 6-methoxyquinoline. Drug Metab and Dispos. 2006 Aug;34(8):1288-90.
  70. Locuson, CW, Wienkers, L.C., Jones, J.P.,  Tracy, T. S.  (2007) “CYP2C9 Protein Interactions with Cytochrome b5: Effects on the Coupling of Catalysis” Drug Metab. and Disp. 35(7): 1174-81.
  71. Kyung-Bin Cho, Yohann Moreau, Devesh Kumar, Dan A. Rock, Jeffrey P. Jones, Sason Shaik (2007) “Formation of the Active Species of Cytochrome P450 by Using Iodosylbenzene: A Case for Spin-Selective Reactivity”  Chemistry: A European Journal, 13: 4103-4115.
  72. Torres, R. A.; Korzekwa, K. R.; McMasters, D. R.; Fandozzi, C. M.; Jones, J. P “Use of Density Functional Calculations To Predict the Regioselectivity of Drugs and Molecules Metabolized by Aldehyde Oxidase” . J. Med. Chem.; (2007) 50(19); 4642-4647.
  73. Hudelson, M. G.; Ketkar, N. S.; Holder, L. B.; Carlson, T. J.; Peng, C. C.; Waldher, B. J.; Jones, J. P. High confidence predictions of drug-drug interactions: predicting affinities for cytochrome P450 2C9 with multiple computational methods. J. Med. Chem. 2008, 51, 648-54.
  74. Peng, C. C.; Rushmore, T.; Crouch, G. J.; Jones, J. P. Modeling and synthesis of novel tight-binding inhibitors of cytochrome P450 2C9. Bioorg Med Chem, 2008, 16, 4064-74.
  75. Peng, C. C., Rushmore, T., Crouch, G. J., Jones, J. P. (2008). “Cytochrome P450 2C9 Type II Binding Studies on Quinoline-4-Carboxamide Analogues” J. Med. Chem, 51 (24): 8000-8011.
  76. Alfaro, J. F., Jones, J. P. (2008). ”Studies on the Mechanism of Aldehyde Oxidase and Xanthine Oxidase.” J Org Chem. 73 (23): 9469-9472.
  77. Alfaro JF, Joswig-Jones CA, Ouyang W, Nichols J, Crouch GJ ,Jones JP, “Purification and Mechanism of Human Aldehyde Oxidase Expressed in Escherichia coli”( 2009) Drug Metab and Dispos. 37 (12) 2393-2398.
  78. Roberts, K.M., Jones, J.P. “Anilinic N-Oxides Support Cytochrome P450-Mediated N-Dealkylation trhough Hydrogen-Atom Transfer” (2010) Chem Eur J. 16, 8096-8107
  79. Peng, C. C., Josh T. Pearson, Dan A. Rock, Carolyn A. Joswig-Jones, Jeffrey P. Jones, The effects of type II binding on metabolic stability and binding affinity in cytochrome P450 CYP3A4, Arch Biochem Biophys, Volume 497, Issues 1-2: 68-81  (2010).
  80. Barr, John, and Jeffrey Jones. “Inhibition of Human Liver Aldehyde Oxidase: Implications for Potential Drug-Drug Interactions.” Drug Metab Dispos: the biological fate of chemicals (2011) doi:10.1124/dmd.111.041806.
  81. Dahal, Upendra P, Jeffrey P Jones, John A Davis, and Dan A Rock. “Small Molecule Quantification by Liquid Chromatography-Mass Spectrometry for Metabolites of Drugs and Drug Candidates.” Drug Metab Dispos: the biological fate of chemicals 39, no. 12 (2011): doi:10.1124/dmd.111.040865.
  82. Jones, Jeffrey P, Carolyn A Joswig-Jones, Michelle Hebner, Yuzhuo Chu, and Dennis R Koop. “The Effects of Nitrogen-Heme-Iron Coordination on Substrate Affinities for Cytochrome P450 2E1.” Chemico-biological interactions 193, no. 1 (2011): doi:10.1016/j.cbi.2011.05.001.
  83. Pearson, Joshua, Upendra P Dahal, Daniel Rock, Chi-Chi Peng, James O Schenk, Carolyn Joswig-Jones, and Jeffrey P Jones. “The Kinetic Mechanism for Cytochrome P450 Metabolism of Type II Binding Compounds: Evidence Supporting Direct Reduction.” Arch Biochem Biophys 511, no. 1-2 (2011): doi:10.1016/j.abb.2011.04.008.
  84. Locuson CW, Alfaro JF, Zaya MJ, Billen D, White JA, Jones JP. “A non-acidic sulfaphenazole analog demonstrating high intrinsic clearance and selectivity by canine CYP2C21.” Drug Metab Lett.  5(4):253-8, (2011)
  85. Hartmann T, Terao M, Garattini E, Teutloff C, Alfaro JF, Jones JP. Leimkühler S. “The impact of single nucleotide polymorphisms on human aldehyde oxidase.”  Drug Metab Dispos. 40(5):856-64, (2012): dmd 40:1-9.
  86. Barr, J. T., and Jones, J. P. (2012) Evidence for Substrate Dependent Inhibition Profiles for Human Liver Aldehyde Oxidase, Drug Metab Dispos . 41:1-6.
  87. Dahal, U. P., Joswig-Jones, C., and Jones, J. P. (2012) Comparative study of the affinity and metabolism of type I and type II binding quinoline carboxamide analogues by cytochrome P450 3A4, J Med Chem 55, 280-290.
  88. Poudel, K.R., Jones, J.P., and Brozik, J.A. “A Guide to Tracking Single Transmembrane Proteins in Supported Lipid Bilayers” Methods in Molecular Biology, Chapter 11, Springer Press, Vol. 974, Editor: Jorg Kleinschmidt, ISBN: 978-1-62703-274-2, February 28, 2013.
  89. Jones, J.P. and Korzekwa, K.R. (2013) Predicting Intrinsic Clearance for Drugs and Drug Candidates Metabolized by Aldehyde Oxidase, Mol. Pharmaceutics, Article ASAP DOI: 10.1021/mp300568r.
  90. Barr, J. T., and Jones, J. P. (2013) “Evidence for substrate-dependent inhibition profiles for human liver aldehyde oxidase”, Drug Metab Dispos 41, 24-29.
  91. Choughule, K. V., Barr, J. T., and Jones, J. P. (2013) “Evaluation of rhesus monkey and Guinea pig hepatic cytosol fractions as models for human aldehyde oxidase”, Drug Metab Dispos 41: 1852-1858.
  92. Sanchez, E. J., Hayes, R. P., Barr, J. T., Lewis, K. M., Webb, B. N., Subramanian, A. K., Nissen, M. S., Jones, J. P., Shelden, E. A., Sorg, B. A., Fill, M., Schenk, J. O., and Kang, C. (2013) Potential role of cardiac calsequestrin in the lethal arrhythmic effects of cocaine, Drug and Alcohol Dependence ASAP.
  93. JT Barr, JP Jones, CA Joswig-Jones, DA Rock (2013) Absolute Quantification of Aldehyde Oxidase Protein in Human Liver Using Liquid Chromatography–Tandem Mass Spectrometry, Molecular Pharmaceutics 2013 10 (10), 3842-3849.
  94. Weidert,E.R., Schoenborn,S.O., Cantu-Medellin,N., Choughule,K.V., Jones,J.P., Kelley,E.E. (2014) Inhibition of xanthine oxidase by the aldehyde oxidase inhibitor raloxifene: Implications for identifying molybdopterin nitrite reductases, Nitric Oxide, 37:41–45.
  95.  Barr,J.T., Choughule,K., Nepal,S., Wong, T., Chaudhry,A.S., Joswig-Jones,C.A., Zientek, M.A., Strom, S., Schuetz,E.G., Thummel,K., Jones,J.P. (2014) Why Do Most Human Liver Cytosol Preparations Lack Xanthine Oxidase Activity? Drug Metab Dispos 113.056374.
  96. Barr, J. T., Choughule, K. V., Jones, J. P (2014) “ Enzyme Kinetics, Inhibition, and Regioselectivity of Aldehyde Oxidase” Enzyme Kinetics in Drug Metabolism: Fundamentals and Applications, Chapter 9, Humana Press, Editors: S Nagar, U A Argikar and D J Tweedie, Methods Mol Biol. Vol. 1113, ISBN: 978-1-62703-757-0.
  97. Choughule, K. V., Barnaba, C., Joswig-Jones, C. A., and Jones, J. P. (2014) In vitro oxidative metabolism of 6-mercaptopurine in human liver: insights into the role of the molybdoflavoenzymes aldehyde oxidase, xanthine oxidase, and xanthine dehydrogenase, Drug Metab Dispos 42, 1334-1340.
  98. Green, A. R., Lewis, K. M., Barr, J. T., Jones, J. P., Lu, F., Ralph, J., Vermerris, W., Sattler, S. E., and Kang, C. (2014) Determination of the Structure and Catalytic Mechanism of Sorghum bicolor Caffeic Acid O-Methyltransferase and the Structural Impact of Three brown midrib12 Mutations, Plant Physiol 165, 1440-1456
  99. Nagar, S., Jones, J. P., and Korzekwa, K. (2014) A numerical method for analysis of in vitro time-dependent inhibition data. Part 1. Theoretical considerations, Drug Metab Dispos 42, 1575-1586.
  100. Barr, J. T., Jones, J. P., Oberlies, N. H., and Paine, M. F. (2015) Inhibition of human aldehyde oxidase activity by diet-derived constituents: structural influence, enzyme-ligand interactions, and clinical relevance, Drug Metab Dispos 43, 34-41.
  101. Sodhi JK, Wong S, Kirkpatrick DS, Liu L2, Khojasteh SC, Hop CE, Barr JT, Jones JP, Halladay JS. (2015) A novel reaction mediated by human aldehyde oxidase: amide hydrolysis of GDC-0834. Drug Metab Dispos. 2015 Jun;43(6):908-15.
  102. Choughule KV, Joswig-Jones CA, Jones JP. (2015) Interspecies differences in the metabolism of methotrexate: An insight into the active site differences between human and rabbit aldehyde oxidase. Biochemical pharmacology. 2015; 96(3):288-95.
  103. Barden, A. O., Goler, A. S., Humphreys, S. C., Tabatabaei, S., Lochner, M., Ruepp, M. D., Jack, T., Simonin, J., Thompson, A. J., Jones, J. P., and Brozik, J. A. (2015) Tracking individual membrane proteins and their biochemistry: The power of direct observation, Neuropharmacology 98, 22-30. (Impact Factor 5.1)
  104. Zhijun Guo, Irina F Sevrioukova, Eric Hanse, Ilia Denisov, Xia Zhang, Ting-Lan Chiu, Daniel Swedien, Justin Stamschror, Juan Alvarez, William Marerro Ortiz, Monique Morgan, Michael Maher, Kathryn J Chavez, Dafydd Thomas, Young Kyung Bae, Jonathan Henriksen, Beverly Norris, Robert J Schumacher, Henry Wang, Robin Bliss, Haitao Chu, Rebecca Cuellar, Thomas L Poulos, Stephen G Sligar, William Atkins, Stephen Schmechel, Jorge Capdevila, John Falck, Ian Blair, Jeffrey P Jones, Gunda Georg, Kalpna Gupta, Ameeta Kelekar, Elizabeth Amin, David A Potter, (2015) CYP3A4 epoxygenase activity mediates ER+ mammary tumor growth and angiogenesis, in part, through EET biosynthesis and is inhibited by biguanides, Cancer Research 75 (15 Supplement), 3568-3568
  105. Scott, E. E., Wolf, C. R., Otyepka, M., Humphreys, S. C., Reed, J. R., Henderson, C. J., McLaughlin, L. A., Paloncyova, M., Navratilova, V., Berka, K., Anzenbacher, P., Dahal, U. P., Barnaba, C., Brozik, J. A., Jones, J. P., Estrada, F., Laurence, J. S., Park, J. W., and Backes, W. L. (2016) The Role of Protein-Protein and Protein-Membrane Interactions on P450 Function, Drug Metab Dispos 44, 576-590. (Impact Factor 3.3)
  106. Barnaba, C., Humphreys, S. C., Barden, A. O., Jones, J. P., and Brozik, J. A. (2016) Substrate Dependent Native Luminescence from Cytochromes P450 3A4, 2C9, and P450cam, J Phys Chem B 120, 3038-3047. (Impact Factor 3.3)
  107. Barnaba, C., Yadav, J., Nagar, S., Korzekwa, K., and Jones, J. P. (2016) Mechanism-Based Inhibition of CYP3A4 by Podophyllotoxin: Aging of an Intermediate Is Important for in Vitro/in Vivo Correlations, Mol Pharm 13, 2833-2843. (Impact Factor 4.4)
  108. Walker, A. M., Sattler, S. A., Regner, M., Jones, J. P., Ralph, J., Vermerris, W., Sattler, S. E., and Kang, C. (2016) The Structure and Catalytic Mechanism of Sorghum bicolor Caffeoyl-CoA O-Methyltransferase, Plant Physiol 172, 78-92. (Impact Factor 6.8)
  109. Moural, T. W., Lewis, K. M., Barnaba, C., Zhu, F., Palmer, N. A., Sarath, G., Scully, E. D., Jones, J. P., Sattler, S. E., and Kang, C. (2017) Characterization of Class III Peroxidases from Switchgrass, Plant Physiol 173, 417-433. (Impact Factor 6.8)
  110. Paragas, EM , Humphreys, SC, Min, J, Joswig-Jones, CA,  Leimkühler, S, Jones, JP,  (2017) ecoAO: A Simple System for the Study of Human Aldehyde Oxidases Role in Drug Metabolism, ACS omega 2 (8), 4820-4827
  111. Paragas, EM, Humphreys, SC, Min, J, Joswig-Jones, CJ, Jones, JP, (2017) The two faces of aldehyde oxidase: Oxidative and reductive transformations of 5-nitroquinoline, Biochemical Pharmacolog
  112. Davydov,DR, Davydova, NY, Rodgers, JT, Rushmore, TH, Jones, JP (2017) Toward a systems approach to the human cytochrome P450 ensemble: interactions between CYP2D6 and CYP2E1 and their functional consequences, Biochemical Journal 474 (20), 3523-3542